Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01896479 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT01896479 · ClinicalTrials.gov record · last posted 2025-09-02

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Study acronym: EXAMINER
StatusActive, Not Recruiting
PhasePhase 4
SponsorExelixis
Started2015-02-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate (ORR) with fewer adverse events compared to the PFS, ORR and adverse events found in previous clinical trials of 140 mg.

Amendment record 21 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 21 times since 2013-07-08; most recent amendment 2025-08-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2020-06-30
Status change Recruiting→Active, Not Recruitingv12
2015-01-22
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT01896479
Lead Sponsor Exelixis
Conditions Medullary Thyroid Cancer
Enrollment 247 participants
Start Date 2015-02-25
Primary Completion 2020-07-15 (estimated)
Study Completion 2035-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-02